After we stopped a Kaufempfehlung for the HIMS-Aktien party, Kursziel got an insight into the Adiposity-Trends from Investing.com

Canaccord Genuity takes over the time off for the Aktien of Hims & Hers Health, Inc. (NYSE:) with an unpaid share price of US$24.00. The concrete business of the American companies in the United States as a healthy reformation, will be upholstered more like the American economies as adipös or über-weight. This trend has a long-term care with diabetes and a herz-kreislauf-erkrankung, which your average costs of 1.5 billion US dollars in health care with adiposity beitragen.

The analyst knows that the GLP-1 agonists discovered the disease of Type 2 Diabetes, but a new analysis of weight management has revealed one of the results of the weight loss. In 2022 it was time for an Engpass at those Medikamenten, for Telemedizin-Plattformen with Hims & Hers die Moeglichkeit eröffnete, together with the different versions of those Medikamente tenders. Obwohl Tirzepatid kürzlich von der FDA-Engpassliste gestrichen wurde, bleibt Semaglutid knapp.

Trotz der Erwartung, het Semaglutid-schließlich besser that is in the world, bestht the overseas, that Hims & Hers weiterhin personalisierte sisterammengesetzte GLP-1-Medikamente anbieten kann. The sick patient population in the US at this price was estimated at between 2.7 and 3.2 million people, a combined addressable market (TAM) of approximately 6 to 8 billion US dollars.

The analysis of the company’s deutet darauf hind, that Hims & Hers derzeit nur one of the economic growth of the market, and your sister market office can be an Erhöhung der Finanzprognoses des Unternehmens führen. The Hims & Hers campaign has been working 100% for years, but a Drittel will start with the GLP-1 coupling in most cases.

Het Wachstum der Coreproducts van de Unternehmens, die sich jährlich een über 40% erweitern, together with de beste Margenverbesserungen und een nach Ansicht van Canaccord Genuity is een nunünftige Bewertung von 2-fachen des Umsatzes voor de Geschäftsjahr 2025, fuhrt zu der Check the operation of Multiple The operation of the device or the GLP-1-Chance is not fully available.

In others active post-war Hims & Hers Health, Inc. Gegenstand more merkswerter Entwicklungen. Financing the stocks in the Small-cap S&P 600 Index, which Truist Securities notes, takes the company and its potential investments. The market is displayed if you focus on Weight Watchers, the lawtbewerb in the wellness environment that can help you.

Darüber could use the Hims & Hers plan, in combination with a single procedure, during the separation of the FDA, the drug list from the English list of tests, which would be infiltrated, an entity, which would be the best possible wurde.

In financing the financial loan, Hims & Hers reported a 52% increase in annual revenue of US$316 million in the 2024 quarter, while generating EBITDA of US$39 million. The Unternehmen go to 976.341 Class A Stammaktien at Nivagen Pharmaceuticals, Inc. in the United States of MedisourceRx, a Schritt, of the product and the market pasture of the Unternehmens.

For 2024, Hims & Hers Health forecasts an amount of 1.37 million and 1.4 billion US dollars, with a net EBITDA of 140 million and 155 million US dollars.

In a joint orientation initiative that Hims & Hers has started a Service Appreciation Initiative, the weight reductions for US military personnel, veterans, military personnel, sick leavers and veterans are offered. The analysts’ analyzes vary between the view that Citi has a neutral rating, Needham has initiated a Kauf-Rating and Jefferies has received its Kursziel. Deutsche Bank takes into account its medical expenses and concrete pouring of the Wachstumsaussichten des Unternehmens.

InvestingPro Acknowledgment

Hims & Hers Health, Inc. (NYSE:HIMS) has made a financial investment that boosts Canaccord Genuity’s maximum Ausblick. Laut InvestingPro-Daten lie on the US stock price in the last month of the month with a decline of 50.15%, while the four-month price in the quarter of 2024 is 51.82% erreichte. This robust Wachstum has led the Analysts’ Ansicht on the expanding Kernangebote of the Unternehmens.

InvestingPro-Tips have increased net profits over these years and allowed analysts to make predictions on how profitable they can become. It stimulates the positive development of the company for Hims & Hers’ financial business. Ensure that the strong representation of the shares in the month (16.9%) and the years (180.22%) of the turnover of investors in their Wachstumspotenzial is shown more broadly, shown in the background on the article GLP-1- Chance.

It is a fact that Hims & Hers was trading at a high KGV of 185.68, was one of the investors holding their high Wachstum backlogs. This Bewertungskennzahl, combined with the market capitalization of the Unternehmens of 3.86 Mil

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.